JP2025515076A5 - - Google Patents
Info
- Publication number
- JP2025515076A5 JP2025515076A5 JP2024564870A JP2024564870A JP2025515076A5 JP 2025515076 A5 JP2025515076 A5 JP 2025515076A5 JP 2024564870 A JP2024564870 A JP 2024564870A JP 2024564870 A JP2024564870 A JP 2024564870A JP 2025515076 A5 JP2025515076 A5 JP 2025515076A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- subject
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338410P | 2022-05-04 | 2022-05-04 | |
| US63/338,410 | 2022-05-04 | ||
| PCT/US2023/020944 WO2023215443A1 (en) | 2022-05-04 | 2023-05-04 | Compositions and methods for the treatment of neuromyelitis optica spectrum disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515076A JP2025515076A (ja) | 2025-05-13 |
| JP2025515076A5 true JP2025515076A5 (cg-RX-API-DMAC7.html) | 2026-05-12 |
Family
ID=88647020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564870A Pending JP2025515076A (ja) | 2022-05-04 | 2023-05-04 | 視神経脊髄炎スペクトラム障害の治療のための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20260022164A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4519312A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515076A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251727A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215443A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3161271A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
| WO2025221479A1 (en) * | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201791366A1 (ru) * | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| US20200095307A1 (en) * | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| CA3161271A1 (en) * | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
-
2023
- 2023-05-04 US US18/861,494 patent/US20260022164A1/en active Pending
- 2023-05-04 EP EP23800012.9A patent/EP4519312A4/en active Pending
- 2023-05-04 WO PCT/US2023/020944 patent/WO2023215443A1/en not_active Ceased
- 2023-05-04 JP JP2024564870A patent/JP2025515076A/ja active Pending
- 2023-05-04 CA CA3251727A patent/CA3251727A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517236A5 (cg-RX-API-DMAC7.html) | ||
| AU2017325240B9 (en) | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X | |
| JP7293122B2 (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| US20200079871A1 (en) | Treatment for multiple myeloma (mm) | |
| JP2023533030A5 (cg-RX-API-DMAC7.html) | ||
| JP2020535149A5 (cg-RX-API-DMAC7.html) | ||
| JP2022536469A5 (cg-RX-API-DMAC7.html) | ||
| JP2022524204A (ja) | 自己抗体介在性自己免疫疾患の処置のための、抗cd38抗体及びその医薬組成物 | |
| WO2018220040A1 (en) | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment | |
| AU2020382850A1 (en) | Type I interferon inhibition in systemic lupus erythematosus | |
| AU2023375340A1 (en) | Methods for the treatment of cardiovascular disease | |
| JP2023504209A5 (cg-RX-API-DMAC7.html) | ||
| JP2022520107A5 (cg-RX-API-DMAC7.html) | ||
| JP2023546503A5 (cg-RX-API-DMAC7.html) | ||
| JP2023510854A5 (cg-RX-API-DMAC7.html) | ||
| JP2022514561A5 (cg-RX-API-DMAC7.html) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| JP2024540294A5 (cg-RX-API-DMAC7.html) | ||
| JP2021522241A5 (cg-RX-API-DMAC7.html) | ||
| JP2023546504A5 (cg-RX-API-DMAC7.html) | ||
| JP2023527059A5 (cg-RX-API-DMAC7.html) | ||
| JP2023506779A5 (cg-RX-API-DMAC7.html) | ||
| WO2025045766A1 (en) | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same | |
| JP2024526742A5 (cg-RX-API-DMAC7.html) | ||
| Léger | A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy |